Update: Improvement strategies for peptide receptor scintigraphy and radionuclide therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 2, 2008, Pages 137-157

  De Visser, Monique ^a   Verwijnen, Suzanne M ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Combination therapy; Radionuclide therapy; Receptor targeting peptides

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BOMBESIN; CAMPTOTHECIN; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GASTRIN; GASTRIN RELEASING PEPTIDE RECEPTOR; GEMCITABINE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LUTETIUM 177; OCTREOTIDE; PENTETATE INDIUM IN 111; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; TYROSINE; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

BINDING AFFINITY; CANCER CLASSIFICATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG BINDING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; ISOTOPE LABELING; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN TARGETING; RADIATION DOSE; RADIOACTIVITY; RECEPTOR UPREGULATION; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER;

ANIMALS; HUMANS; NEOPLASMS; PEPTIDES; RADIOISOTOPES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE;

EID: 43249088881     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0435     Document Type: Review

References (173)

1. Krenning EP, Teunissen JJ, Valkema R, et al. Molecular radiotherapy with somatostatin analogs for (neuro) endocrine tumors. J Endocrinol Invest 2005;28:146.
2. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716.
3. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704.
4. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin Nucl Med 2002;32:110.
5. 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 2003;30:207.
6. 3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147.
7. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439.
8. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610.
9. Chinol M, Bodei L, Cremonesi M, et al. Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: The experience of the European Institute of Oncology Group. Semin Nucl Med 2002;32:141.
10. van Essen M, Krenning EP, de Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 2007;46:723.
11. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273.
12. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437.
13. Esser JP, Krenning EP, Teunissen JJ, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: Which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006;33:1346.
14. 111In-DT- PAo] octreotide in patients. Eur J Nucl Med 2001;28:1319.
15. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902.
16. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl. 1):13S.
17. 3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754.
18. 3]octreotate. J Clin Oncol 2004;22:2724.
19. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004;64:6707.
20. Breeman WA, Hofland LJ, de Jong M, et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999;81:658.
21. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006;103:16436.
22. 111In-DTPA- octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003;44:708.
23. 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med 2000;27:628.
24. 99mTc-EDDA/HYNIC-octreotate in detection of atypical bronchial carcinoid. Exp Clin Endocrinol Diabetes 2007;115:47.
25. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: Results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123.
26. 99m)Tc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET: A case of metastatic duodenal carcinoid. Nucl Med Rev Cent East Eur 2005;8:155.
27. 3] octreotide: An intrapatient comparison of two novel technetium-99m-labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm 2004;19:73.
28. 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice. J Pept Sci 2006;12:124.
29. 99mTc-Demotate 1: First data in tumour patients - results of a pilot/phase I study. Eur J Nucl Med Mol Imaging 2003;30:1211.
30. 111In]DTPA- octreotide. J Nucl Med 2006;47:566.
31. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213.
32. 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478.
33. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42.
34. 3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508.
35. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52.
36. Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836.
37. Ginj M, Schmitt JS, Chen J, et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol 2006;13:1081.
38. 68Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;32:724.
39. Reubi JC, Wenger S, Schmuckli-Maurer J, et al. Bombesin receptor subtypes in human cancers: Detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 2002;8:1139.
40. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43.
41. 3 derivatives of octreotide in rats. Anticancer Res 1998;18:83.
42. 99m)Tc] Demobesin 1, a novel potent bombesin analogue for GRP-receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:247.
43. 99mTc: A preclinical study. J Med Chem 2005;48:100.
44. 99m RP527, a GRP analogue for visualisation of GRP-receptor- expressing malignancies: A feasibility study. Eur J Nucl Med 2000;27:1694.
45. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205.
46. 111In- labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003;44:823.
47. 111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 2002;43:1650.
48. 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun 2006;27:371.
49. 99m)Tc](CO)(3) bombesin analogues. Nucl Med Biol 2007;34:17.
50. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46(Suppl.1):67S.
51. 111)In- labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging 2007;34:1228.
52. Zhang H, Schuhmacher J, Waser B, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1198.
53. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006;33:371.
54. Smith CJ, Gali H, Sieckman GL, et al. Radiochemical investigations of (177)Lu-DOTA-8-Aoc-BBN[7-14]NH(2): An in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 2003;30:101.
55. 64Cu-labeled bombesin analogue. Bioconjug Chem 2003;14:756.
56. Johnson CV, Shelton T, Smith CJ, et al. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP-receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 2006;21:155.
57. Biddlecombe GB, Rogers BE, Visser MD, et al. Molecular imaging of gastrin-releasing peptide-receptor-positive tumors in mice using (64)Cu- and (86) Y-DOTA-(Pro(1),Tyr(4))-Bombesin(1-14). Bioconjug Chem 2007.
58. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006;47:1144.
59. Van de Wiele C, Dumont F, van Belle S, et al. Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? Nucl Med Commun 2001;22:5.
60. Baum R, Prasad V, Mutloka N, et al. Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: First results. J Nucl Med 2007;48:79P.
61. de Visser M, van Weerden WM, Melis M, et al. Radiolabeled bombesin analogs in preclinical studies. J Nucl Med 2007;48 (Suppl. 2):24P.
62. Mancuso A, Oudard S, Sternberg CN. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): Present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 2007;61:176.
63. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23:3343.
64. de Visser M, van Weerden WM, de Ridder CM, et al. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J Nucl Med 2007;48:88.
65. de Jong M, Breeman WA, Bernard BF, et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841.
66. 3] octreotate for somatostatin-receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628.
67. De Jong M, Valkema R, Jamar F, et al. Somatostatin-receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002;32:133.
68. Reubi JC, Waser B, Friess H, et al. Neurotensin receptors: A new marker for human ductal pancreatic adenocarcinoma. Gut 1998;42:546.
69. Kuhar MJ. Imaging receptors for drugs in neural tissue. Neuropharmacology 1987;26:911.
70. Ehlers RA, Kim S, Zhang Y, et al. Gut-peptide-receptor expression in human pancreatic cancers. Ann Surg 2000;231:838.
71. 99mTc-labeled neurotensin peptide 8-13. Nucl Med Biol 2006;33:505.
72. 99mTc. J Med Chem 2006;49:4767.
73. 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J Med Chem 2006;49:1833.
74. Garcia-Garayoa E, Maes V, Blauenstein P, et al. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors. Nucl Med Biol 2006;33:495.
75. Garcia-Garayoa E, Allemann-Tannahill L, Blauenstein P, et al. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 2001;28:75.
76. Lugrin D, Vecchini F, Doulut S, et al. Reduced peptide bond pseudopeptide analogues of neurotensin: Binding and biological activities and in vitro metabolic stability. Eur J Pharmacol 1991;205:191.
77. de Visser M, Janssen PJ, Srinivasan A, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 2003;30:1134.
78. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109.
79. 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 2003;44:1649.
80. Reubi JC, Chayvialle JA, Franc B, et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64:567.
81. Kwekkeboom DJ, Reubi JC, Lamberts SW, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413.
82. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-Aand CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57:1377.
83. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998;25:424.
84. Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998;25:481.
85. 111In-labeled nonsulfated CCK8 analog: A peptide for CCK-B-receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999;40:2081.
86. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000;27:1312.
87. Behr TM, Jenner N, Behe M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029.
88. 99m)Tc-labeled minigastrin analogs. J Nucl Med 2005;46:1727.
89. Gotthardt M, Behe MP, Beuter D, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006;33:1273.
90. Gotthardt M, Behe MP, Grass J, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 2006;13:1203.
91. Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003;55:167.
92. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781.
93. Korner M, Stockli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J Nucl Med 2007;48:736.
94. Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005;21:91.
95. 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl Med Biol 1999;26:413.
96. Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: Initial experimental results. Eur J Nucl Med Mol Imaging 2002;29:597.
97. Gotthardt M, Lalyko G, van Eerd-Vismale J, et al. A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents. Regul Pept 2006;137:162.
98. 2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006;47:2025.
99. 2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007;13:3696.
100. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer 1996;32A:2423.
101. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000;275:21785.
102. Gurrath M, Muller G, Kessler H, et al. Conformation/ activity studies of rationally designed potent antiadhesive RGD peptides. Eur J Biochem 1992;210:911.
103. Aumailley M, Gurrath M, Muller G, et al. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991;291:50.
104. van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000;90:186.
105. 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41.
106. 18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD-peptide-based tracer for PET imaging of alpha v-beta-3 integrin expression. J Nucl Med 2006;47:1172.
107. 18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15:61.
108. 18F]galacto-RGD identifies the level of integrin alpha(v)beta-3 expression in man. Clin Cancer Res 2006;12:3942.
109. 18F-galacto-RGD, a new radiotracer for imaging alpha v-beta3-expression. J Nucl Med 2006;47:763.
110. 18F-galacto-RGD in cancer patients. J Nucl Med 2005;46:1333.
111. Dijkgraaf I, Kruijtzer JA, Liu S, et al. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 2007;34:267.
112. Dijkgraaf I, Rijnders AY, Soede A, et al. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: Implications for tumor targeting and tumor imaging purposes. Org Biomol Chem 2007;5:935.
113. 111In-labeled RGD peptide. Nucl Med Biol 2007;34:29.
114. Dijkgraaf I, Kruijtzer JA, Frielink C, et al. Alpha-v-beta-3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 2007;120:605.
115. Kimura N, Hayafuji C, Konagaya H, et al. 17-beta-estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells. Endocrinology 1986;119:1028.
116. Presky DH, Schonbrunn A. Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem 1988;263:714.
117. Kimura N, Hayafuji C, Kimura N. Characterization of 17-beta-estradiol- dependent and -independent somatostatin receptor subtypes in rat anterior pituitary. J Biol Chem 1989;264:7033.
118. Slama A, Videau C, Kordon C, et al. Estradiol regulation of somatostatin receptors in the arcuate nucleus of the female rat. Neuroendocrinology 1992;56:240.
119. Vidal C, Rauly I, Zeggari M, et al. Upregulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells. Mol Pharmacol 1994;46:97.
120. Visser-Wisselaar HA, Van Uffelen CJ, Van Koetsveld PM, et al. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology 1997;138:1180.
121. Froidevaux S, Hintermann E, Torok M, et al. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 1999;59:3652.
122. Viguerie N, Esteve JP, Susini C, et al. Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells. Biochem Biophys Res Commun 1987;147:942.
123. 111In-pentetreotide: Is there evidence of somatostatin receptor downregulation? J Nucl Med 2006;47:354.
124. Béhé M, Püsken M, Henzel M, et al. Upregulation of gastrin and somatostatin receptor after irradiation. Eur J Nucl Med Mol Imaging 2003;30:S218.
125. Béhé M, Koller S, Püsken M, et al. Irradiation-induced upregulation of somatostatin and gastrin receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging 2004;31:S237.
126. Oddstig J, Bernhardt P, Nilsson O, et al. Radiation-induced upregulation of somatostatin receptor expression in small-cell lung cancer in vitro. Nucl Med Biol 2006;33:841.
127. 111In-labelled somatostatin analogues in a rat tumour model: Somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2005;32:1288.
128. 3]octreotate therapy. Q J Nucl Med 2007.
129. Seth P. Vector-mediated cancer gene therapy: An overview. Cancer Biol Ther 2005;4:512.
130. 1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clin Cancer Res 1999;5:383.
131. Zinn KR, Chaudhuri TR, Buchsbaum DJ, et al. Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging. Nucl Med Biol 2001;28:135.
132. Hemminki A, Belousova N, Zinn KR, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001;4:223.
133. Zinn KR, Chaudhuri TR, Krasnykh VN, et al. Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology 2002;223:417.
134. Hemminki A, Zinn KR, Liu B, et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 2002;94:741.
135. Rogers BE, Zinn KR, Lin CY, et al. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human non-small-cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer 2002;94:1298.
136. Payne CM, Bjore CG, Jr, Schultz DA. Change in the frequency of apoptosis after low- and high-dose X-irradiation of human lymphocytes. J Leukoc Biol 1992;52:433.
137. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274.
138. Buchsbaum DJ, Chaudhuri TR, Yamamoto M, et al. Gene expression imaging with radiolabeled peptides. Ann Nucl Med 2004;18:275.
139. ter Horst M, Verwijnen SM, Brouwer E, et al. Locoregional delivery of adenoviral vectors. J Nucl Med 2006;47:1483.
140. Gotthardt M, Librizzi D, Wolf D, et al. Increased therapeutic efficacy through combination of Lu-177-DOTATOC and chemotheray in neuroendocrine tumours in vivo. Eur J Nucl Med Mol Imaging 2006;33:S115.
141. 111 octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors. J Nucl Med 2005;46:151P.
142. 111In-DTPA])]-exendin-4 and VEGF-receptor tyrosine kinase inhibitor PTK in a glucagon-like-peptide-1 receptor-positive transgenic mouse tumor model. J Nucl Med 2007;48(Suppl. 2):83P.
143. Fueger BJ, Hamilton G, Raderer M, et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med 2001;42:1856.
144. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1.
145. Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone, and bombesin to cancers expressing their receptors: A "smarter" chemotherapy. Curr Pharm Des 2005;11:1167.
146. Hofland LJ, Capello A, Krenning EP, et al. Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. J Nucl Med 2005;46(Suppl.1):191S.
147. Keller G, Schally AV, Nagy A, et al. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multidrug resistance proteins. Int J Oncol 2006;28:1507.
148. Engel JB, Schally AV, Halmos G, et al. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 2005;104:1312.
149. Buchholz S, Keller G, Schally AV, et al. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc Natl Acad Sci USA 2006;103:10403.
150. Kanashiro CA, Schally AV, Nagy A, et al. Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and anti-apoptotic mechanisms. Int J Oncol 2005;27:169.
151. Kiaris H, Schally AV, Nagy A, et al. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res 2000;6:709.
152. Szereday Z, Schally AV, Nagy A, et al. Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215. Br J Cancer 2002;86:1322.
153. Moody TW, Fuselier J, Coy DH, et al. Camptothecin-somatostatin conjugates inhibit the growth of smallcell lung cancer cells. Peptides 2005;26:1560.
154. Sun LC, Luo J, Mackey LV, et al. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphavbeta3/alphavbeta5, and MMP-2/-9. Cancer Lett 2007;246:157.
155. Moody TW, Sun LC, Mantey SA, et al. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther 2006;318:1265.
156. Sun LC, Luo J, Mackey VL, et al. Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs 2007;18:341.
157. 3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm 2004;19:173.
158. Capello A, Krenning EP, Bernard BF, et al. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 2004;45:1716.
159. Capello A, Krenning EP, Bernard BF, et al. Anticancer activity of targeted proapoptotic peptides. J Nucl Med 2006;47:122.
160. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999;397:534.
161. Lambert B, Cybulla M, Weiner SM, et al. Renal toxicity after radionuclide therapy. Radiat Res 2004;161:607.
162. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with three radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl. 1):62S.
163. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)- octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46(Suppl. 1):83S.
164. Melis M, Krenning EP, Bernard BF, et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 2005;32:1136.
165. 111)In-DTPA] octreotide. J Nucl Med 2004;45:1168.
166. 111)In-DTPA-octreotide. J Nucl Med 2005;46:1696.
167. Rolleman EJ, Kooij PP, de Herder WW, et al. Somatostatin-receptor- subtype-2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging 2007;34:1854.
168. 111In-DTPA]octreotide. J Nucl Med 2005;46:2057.
169. 111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929.
170. 111In-octreotide in mice and rats. J Nucl Med 2006;47:528.
171. Vegt E, Wetzels JF, Russel FG, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006;47:432.
172. 0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med 2004;45:709.
173. Rolleman EJ, Forrer F, Bernard B, et al. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [(177)Lu-DOTA (0),Tyr (3)]octreotate. Eur J Nucl Med Mol Imaging 2007;34:763.